Eisai and Purdue Report Result of Lemborexant in P-III SUNRISE 2 Study for Insomnia in Adults

 Eisai and Purdue Report Result of Lemborexant in P-III SUNRISE 2 Study for Insomnia in Adults

Eisai and Purdue Report Result of Lemborexant in P-III SUNRISE 2 Study for Insomnia in Adults

Shots:

  • The P-III SUNRISE 2 study involves assessing of Lemborexant (5mg,10mg) vs PBO in 949 patients with insomnia disorder, characterized by difficulty in falling asleep/staying asleep aged 18 to 88yrs.
  • P-III SUNRISE 2 study results: reductions in sleep onset latency (sSOL) (-21.81, -28.21 vs -11.43 min); improvement in sSE (14.19%, 14.31% vs 9.64%); reduction in subjective wake after sleep onset (sWASO) (-46.75, -41.95 vs -29.28 min); presented at Sleep Research Society’s on 14 Feb, 2019
  • Lemborexant is an orexin neurotransmitter targeted for faster falling asleep with longer period of time with its NDA filled with the US FDA for insomnia on 27 Dec,2018 and is evaluated in P-II for sleep-wake rhythm disorder and mild to moderate Alzheimer’s dementia


Click here  to read full press release/ article | Ref: PRNewswire | Image: Bizjournals

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post